Light therapy added to lung rehabilitation for people with COPD
Tests light therapy alongside lung rehabilitation in adults with chronic obstructive pulmonary disease.
Plain-language title generated from the registry record
Registry title: PBMT Associated With a Pulmonary Rehabilitation Program on the Functional Capacity of Patients With COPD
Key facts
- Where
- Porto Alegre, BrazilSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT07878884, who can take part
Where in Brazil
- Santa Casa de Porto AlegrePorto Alegre, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Federal University of Health Science of Porto Alegre
- Trial code
- NCT07878884
- Record updated
- 16 October 2026
- Original description
This study aims to evaluate the effectiveness of photobiomodulation therapy (PBMT) as an adjunct to the pulmonary rehabilitation program on the functional capacity of patients with COPD. This is a randomized, placebo-controlled, double-blind clinical trial conducted with 20 patients from the outpatient clinic of the Integrated Cardiopulmonary and Metabolic Rehabilitation Service of Santa Casa de Porto Alegre. Patients will be allocated to the active PBMT group, receiving photobiomodulation treatment prior to the exercise protocol of the pulmonary rehabilitation program, in the respiratory and peripheral muscles, or the placebo group, which will receive the therapy application at the same points but without the therapeutic dose, prior to rehabilitation. Sixteen PBMT applications will be performed over eight weeks, with a frequency of twice a week. The exercises performed in the institution's pulmonary rehabilitation program by the patients will not be interfered with by the researchers. Evaluations will be carried out in three stages: immediately after recruitment, after 8 interventions, and after 16 interventions.Read full original descriptionShow less
Photobiomodulation Therapy (PBMT) Associated With a Pulmonary Rehabilitation Program on the Functional Capacity of Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Placebo-controlled, Double-blind Clinical Trial.
This study aims to evaluate the effectiveness of photobiomodulation therapy (PBMT) as an adjunct to the pulmonary rehabilitation program on the functional capacity of patients with COPD. This is a randomized, placebo-controlled, double-blind clinical trial conducted with 20 patients from the outpatient clinic of the Integrated Cardiopulmonary and Metabolic Rehabilitation Service of Santa Casa de Porto Alegre. Patients will be allocated to the active PBMT group, receiving photobiomodulation treatment prior to the exercise protocol of the pulmonary rehabilitation program, in the respiratory and peripheral muscles, or the placebo group, which will receive the therapy application at the same points but without the therapeutic dose, prior to rehabilitation. Sixteen PBMT applications will be performed over eight weeks, with a frequency of twice a week. The exercises performed in the institution's pulmonary rehabilitation program by the patients will not be interfered with by the researchers. Evaluations will be carried out in three stages: immediately after recruitment, after 8 interventions, and after 16 interventions.
Inclusion: Patients diagnosed with COPD, in the maintenance phase, with GOLD classification 3 and 4; Ability to walk.
Exclusion: Recent skin lesions or tattoos at the site of therapy application; Patients with sequelae of stroke; Recent acute myocardial infarction (within two months); Uncontrolled hypertension; Heart failure grade IV according to the New York Heart Association or decompensated; Unstable angina or arrhythmia; Peripheral vascular alterations in lower limbs such as deep vein thrombosis; Disabling osteoarticular or musculoskeletal disease; Patients with cancer and/or undergoing cancer treatment; Pacemaker or cardiac defibrillator; Cognitive dysfunction that prevents the completion of assessments, as well as inability to understand and sign the informed consent form (ICF); Patients with systemic lupus erythematosus; Hemophilia.